Clavanin bacterial sepsis control using a novel methacrylate nanocarrier

Area of Science:

• Marine biotechnology
• Nanomedicine
• Antimicrobial peptides

Background:

• Antimicrobial resistance is a global health challenge, driving research into novel treatments.
• Marine-derived peptides, like clavanins, exhibit potent antimicrobial activity but face pharmaceutical limitations.
• Nanotechnology offers a solution to enhance peptide drug delivery and efficacy.

Purpose of the Study:

• To develop nanoantibiotics by encapsulating clavanin A using nanobiotechnology.
• To evaluate the antimicrobial activity and safety of nanostructured clavanin A.
• To assess the in vivo efficacy of nanoformulated clavanin A in a murine sepsis model.

Main Methods:

• Clavanin A was encapsulated using EUDRAGIT® L 100-55 and RS 30 D solution.
• Nanoparticle characterization included dynamic light scattering and microscopy.
• Encapsulation efficiency was determined by reversed-phase chromatography.
• In vitro and in vivo bioassays were conducted to assess antimicrobial activity and survival rates.

Main Results:

• Nanoparticles ranged from 120 to 372 nm with a high encapsulation rate of 98%.
• Nanostructured clavanin A demonstrated partial control over Staphylococcus aureus, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
• The nanostructures exhibited no hemolytic activity, indicating good safety.
• In vivo studies showed 100% survival in sub-lethal and 40% in lethal sepsis models.

Conclusions:

• Nanostructured clavanin A offers improved antimicrobial properties and enhanced delivery.
• Nanoformulated clavanin A shows significant potential for treating polymicrobial infections, including sepsis.
• This approach addresses the pharmaceutical limitations of antimicrobial peptides.